Company Overview and News

1
ATH / Athene Holding Ltd PRE 14A

2018-04-10 sec.gov
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Upvote Downvote

 
Is Athene Holding (ATH) Stock a Solid Choice Right Now?

2018-04-04 zacks
One stock that might be an intriguing choice for investors right now is Athene Holding Ltd. (ATH - Free Report) . This is because this security in the Insurance - Life Insurance space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board.
Upvote Downvote

1
ATH / Athene Holding Ltd 8-K (Current Report)

2018-03-09 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
ATH / Athene Holding Ltd 424B7 (Prospectus)

2018-03-08 sec.gov
424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registration No. 333-222392 CALCULATION OF REGISTRATION FEE
Upvote Downvote

 
Athene Holding (ATH) in Focus: Stock Moves 5.7% Higher

2018-03-08 zacks
Athene Holding Ltd. (ATH - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $46.67 to $49.70 in the past one-month time frame. The company has seen a mixed track record when it comes to estimate revisions of one increase and two decreases over the past one month, while the Zacks Consensus Estimate has moved lower in the said time period.
Upvote Downvote

 
ATH / Athene Holding Ltd / Abu Dhabi Investment Authority - null (Passive Investment)

2018-03-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
ATH / Athene Holding Ltd / Abu Dhabi Investment Authority - null (Passive Investment)

2018-03-07 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
Upvote Downvote

 
ATH / Athene Holding Ltd 424B7 (Prospectus)

2018-03-06 sec.gov
424B7 Table of Contents Filed Pursuant to Rule 424(b)(7) Registraiton No. 333-222392 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. A registration statement relating to these securities became effective under the Securities Act of 1933, as amended. This preliminary prospe
Upvote Downvote

 
BRIEF-Athene Holding Ltd. Adds Independent Board Member Fehmi Zeko

2018-03-02 reuters
* ATHENE HOLDING - ZEKO IS VICE CHAIRMAN OF THE GLOBAL TECHNOLOGY, MEDIA & TELECOMMUNICATIONS INVESTMENT BANKING GROUP FOR BANK OF AMERICA MERRILL LYNCH Source text for Eikon: Further company coverage:
Upvote Downvote

 
Athene Holding's (ATH) CEO Jim Belardi on Q4 2017 Results - Earnings Call Transcript

2018-02-22 seekingalpha
Thank you for joining us today for Athene's Conference Call. [Operator Instructions] Please note that this call is being recorded and is the property of Athene and that any unauthorized broadcast of this call in any form is prohibited.
Upvote Downvote

 
Athene Holding 2017 Q4 - Results - Earnings Call Slides

2018-02-22 seekingalpha
The following slide deck was published by Athene Holding in conjunction with their 2017 Q4 earnings call.
Upvote Downvote

 
ATH / Athene Holding Ltd 8-K (Current Report)

2018-02-21 sec.gov
Document               UNITED STATES SECURITIES AND EXCHANGE COMMISSION               Washington, D.C. 20549                             FORM 8-K                             CURRENT REPORT               PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934               Date of report (Date of earliest event reported): February 21, 2018                               ATHENE HOLDING LTD.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: G0684D107